An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis: results from 19 countries
Jazyk angličtina Země Velká Británie, Anglie Médium print
Typ dokumentu časopisecké články
PubMed
34232315
DOI
10.1093/ehjcvp/pvab052
PII: 6316776
Knihovny.cz E-zdroje
- Klíčová slova
- Audit, Blood pressure, Lipids, Prevention, Rheumatoid arthritis, Statins,
- MeSH
- dyslipidemie * diagnóza farmakoterapie epidemiologie MeSH
- hypertenze * diagnóza farmakoterapie epidemiologie MeSH
- kardiovaskulární nemoci * diagnóza epidemiologie prevence a kontrola MeSH
- lidé MeSH
- lipidy MeSH
- revmatoidní artritida * diagnóza farmakoterapie epidemiologie MeSH
- rizikové faktory MeSH
- statiny * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- lipidy MeSH
- statiny * MeSH
AIMS: To assess differences in estimated cardiovascular disease (CVD) risk among rheumatoid arthritis (RA) patients from different world regions and to evaluate the management and goal attainment of lipids and blood pressure (BP). METHODS AND RESULTS: The survey of CVD risk factors in patients with RA was conducted in 14 503 patients from 19 countries during 2014-19. The treatment goal for BP was <140/90 mmHg. CVD risk prediction and lipid goals were according to the 2016 European guidelines. Overall, 21% had a very high estimated risk of CVD, ranging from 5% in Mexico, 15% in Asia, 19% in Northern Europe, to 31% in Central and Eastern Europe and 30% in North America. Of the 52% with indication for lipid-lowering treatment (LLT), 44% were using LLT. The lipid goal attainment was 45% and 18% in the high and very high risk groups, respectively. Use of statins in monotherapy was 24%, while 1% used statins in combination with other LLT. Sixty-two per cent had hypertension and approximately half of these patients were at BP goal. The majority of the patients used antihypertensive treatment in monotherapy (24%), while 10% and 5% as a two- or three-drug combination. CONCLUSION: We revealed considerable geographical differences in estimated CVD risk and preventive treatment. Low goal attainment for LLT was observed, and only half the patients obtained BP goal. Despite a high focus on the increased CVD risk in RA patients over the last decade, there is still substantial potential for improvement in CVD preventive measures.
1st Medical Faculty Charles University Prague Czech Republic
5 A Nasonova Research Institute of Rheumatology Moscow Russia
Bernhoven Hospital Uden the Netherlands
Center of Cardiology of Russian Ministry of Healthcare Moscow Russia
Department of Internal Medicine University of Manitoba Winnipeg Manitoba Canada
Department of Medicine Division of Rheumatology University of Toronto Toronto Ontario Canada
Department of Rheumatology and Immunology Peking University People's Hospital Beijing 100044 China
Division of Rheumatology Department of Internal Medicine Mayo Clinic Rochester MN USA
Dudley Group NHS Foundation Trust Dudley West Midlands UK
Hospital Universitario 'Dr José E González' UANL Monterrey México
Hospital Universitario Marqués de Valdecilla Santander Spain
Iii Interna klinika fn Olomouc Olomouc Czech Republic
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán México City México
Ivanovo State Medical Academy Ivanovo Russia
Kyrgyz State Medical Academy Bishkek Kyrgyz Republic
National Institute of Rheumatic Diseases 92101 Piešťany Slovensko Slovakia
Spedali Civili and University of Brescia Brescia Italy
Swedish Rheumatoid Arthritis Registry Umeå Sweden
Tallagh University Hospital Dublin Ireland
The Lundquist Institute Harbor UCLA Medical Center Torrance CA USA
Citace poskytuje Crossref.org